Galcanezumab Boosts Brain Connectivity in Migraine Relief

Research Summary

A recent study published in Scientific Reports reveals how galcanezumab, a monoclonal antibody for migraine prevention, influences brain connectivity and long-term clinical outcomes. Researchers examined 15 migraine patients using electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) to assess changes in brain activity and network properties before and after treatment. After three months, patients showed increased global efficiency and higher synergy in brain signals, reaching levels similar to healthy controls. The study found that these neurophysiological improvements correlated with better clinical outcomes after one year, such as reduced migraine-related disability and less frequent use of acute medications, highlighting galcanezumab's central effects.

Study Details

📄 Title: Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome.

👥 Research Team: La Rocca M et al.

📚 Published In: Sci Rep

📅 Publication Date: 2025 Dec 10

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.